TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06040190

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical placebo tablet
Description: Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical clonazepam tablet
Description: Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral alpha-lipoic acid capsule
Description: Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical phytotherapic capsaicin gel
Description: Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local photobiomodulation
Description: Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
Study: NCT06517576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitor with Digital Platform and Health Coaching
Description: Blood glucose monitors will be used daily to measure blood glucose measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous glucose monitors will be used daily to measure blood glucose measurements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care for type 2 diabetes
Study: NCT05578898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEAR Care Companion (CC) application
Description: The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
Study: NCT04975269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Target dose: 500 mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05934604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Healthy subjects will complete two fMRI sessions after initial assessment and training in the Rest Focus Task (RFT). The first session will be the localizer session to identify the networks involved in switching in the RFT. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP\>RECALL contrast.
Study: NCT04276116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary age
Description: Communication of pulmonary age
Study: NCT05813782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Massage
Description: Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
Study: NCT05839197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Description: Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC.
Study: NCT05396456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Fiber Fragment (MFF) Injections
Description: The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
Study: NCT04738747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHOOP fitness tracker
Description: WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
Study: NCT06221202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stories in the Moment Dance Program - Online
Description: Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.
Study: NCT05929677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants receive alcohol intravenously, clamped at BrACs of 20mg%, 40mg%, and 60mg%. They will also have the opportunity to self-administer alcohol (up to 120mg% BrAC) during the 60-minute free-access IV self-administration period in session 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants receive alcohol intravenously, clamped at BrACs of 20mg%, 40mg%, and 60mg%. They will also have the opportunity to self-administer alcohol (up to 120mg% BrAC) during the 60-minute free-access IV self-administration period in session 3.
Study: NCT05620498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab+lenvatinib+GMOX
Description: tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tislelizumab+GEMOX
Description: tislelizumab+GEMOX
Study: NCT06065878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK + Genicular Nerve Block
Description: IPACK and Genicular Nerve block were applied with the same total volume of local anesthetic as the control group.
Study: NCT06536192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model group
Description: 1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam.
Study: NCT05652621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
Study: NCT06114433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: Slide-based presention plus 3D printed educational model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model education
Description: Slide-based presention plus traditional model
Study: NCT03949556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Videos and/or SMS
Description: Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videos and/or SMS
Description: Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
Study: NCT05519384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK500 cell injection，cyclophosphamide，Fludarabine
Description: After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
Study: NCT03949556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos and/or SMS
Description: Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
Study: NCT05073653

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-GRP PET/CT
Description: Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
Study: NCT06046781

Intervention type: OTHER
Group type: OTHER
Intervention: physical exercise
Description: The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
Study: NCT04683822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will attend telerehabilitation sessions
Study: NCT06046781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
Study: NCT05359419

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride gel, 10%
Description: 10% ALA with Red Light

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid HCl topical solution, 20%
Description: 20% ALA with Blue Light
Study: NCT05169918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization
Description: The progressive core stabilization exercise approach created by Kumar et al. will be used.~* Stage 1; Isolation and facilitation of target muscles~* Stage 2; Trunk stabilization training with increased load under static conditions~* Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~* Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization
Description: The progressive core stabilization exercise approach created by Kumar et al. will be used.~* Stage 1; Isolation and facilitation of target muscles~* Stage 2; Trunk stabilization training with increased load under static conditions~* Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~* Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorial Discrimination Training
Description: Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
Study: NCT05832502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GBS6
Description: The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GBS6
Description: The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
Study: NCT05772377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochloride anlotinib
Description: Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 10 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 8mg will be taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum/carboplatin
Description: Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen. For patients who cannot tolerate the toxicity of cisplatin, 75 mg/m2 nedaplatin will be used as an alternative drug.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy and brachytherapy
Description: Radiation will be given by external beam of 40Gy total dose and 3D-brachytherapy of 30Gy/2.5F. Duration of radiotherapy will be no more than 5 weeks
Study: NCT05440513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Pelvic Denervation (bilateral)
Description: Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
Study: NCT05576532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCL2 Inhibitor plus IM2 regimen
Description: oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
Study: NCT06500494

Intervention type: DRUG
Intervention: Vinorelbine Tartrate Oral
Description: The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.

Intervention type: DRUG
Intervention: Vinorelbine Tartrate Oral
Description: The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.
Study: NCT06491771

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TargetCool
Description: The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TargetCool
Description: The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
Study: NCT06244511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Bipedal Exercise
Description: Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Bipedal Exercise
Description: Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
Study: NCT06457425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonoltinib 50mg
Description: Flonoltinib 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonoltinib 100mg
Description: Flonoltinib 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
Study: NCT05976425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ModPG3 Investigational Device
Description: * Connex Vital Sign Monitor with ModPG3~* Laptop~* Data Collection Software~* USB cable~* Power strip~* Welch Allyn FlexiPort Disposable Blood Pressure Cuffs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive Reference Equipment
Description: * Surveyor S12/S19~* Hill-Rom ICU Medical data collection cable DIR 60119852~* Hill-Rom Edwards data collection cable DIR 60119853
Study: NCT06108401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow milk-based infant formula
Description: Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
Study: NCT05673629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Injection in combination with AC
Description: The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injection in combination with AC
Description: The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.
Study: NCT06514092

Intervention type: OTHER
Intervention: anti-TNF therapy and seton drainage
Description: Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.